**Supplementary Table S2.** Demographic and clinical characteristics of kidney transplant recipients (KTR) before (Pre-COV-KTR) or during (COV-KTR) the COVID-19 pandemic: analysis A2.

| Variables | Whole population (N = 360) | Pre-COV-KTR (N = 122) | COV-KTR (N = 238) | $p$ |
|---|---|---|---|---|
| Recipient sex (male) | 205 (56.9) | 71 (58.2) | 134 (56.3) | 0.738 |
| Recipient age (years) | 52 (43–60) | 52 (45–60) | 51 (42–59) | 0.366 |
| Recipient ethnicity: | | | | |
| Caucasian | 324 (90.0) | 111 (91.0) | 213 (89.5) | 0.714 |
| Afro-Caribbean | 7 (1.9) | 1 (0.8) | 6 (2.5) | 0.430 |
| Other | 29 (8.1) | 10 (8.2) | 19 (8.0) | 1.000 |
| Renal replacement therapy | 341 (94.7) | 118 (96.7) | 223 (93.7) | 0.320 |
| Haemodialysis | 276/341 (80.9) | 92/118 (78.0) | 184/223 (82.5) | 0.314 |
| Dialysis vintage (months) | 35 (16–57) | 34 (16–62) | 35 (16–56) | 0.891 |
| Primary kidney disease: | | | | |
| Primary or secondary glomerulonephritis | 173 (48.1) | 56 (45.9) | 107 (45.0) | 0.911 |
| Diabetic nephropathy | 13 (3.6) | 5 (4.1) | 8 (3.4) | 0.769 |
| Polycystic kidney disease | 66 (18.3) | 25 (20.5) | 41 (17.2) | 0.473 |
| Hypertensive nephrosclerosis | 24 (6.7) | 7 (5.7) | 17 (7.1) | 0.664 |
| Tubulointerstitial disease | 12 (3.3) | 3 (2.5) | 9 (3.8) | 0.758 |
| Genetic or congenital kidney disease | 39 (10.8) | 13 (10.7) | 26 (10.9) | 1.000 |
| Uropathy | 42 (11.7) | 12 (9.8) | 30 (12.6) | 0.492 |
| Thrombotic microangiopathy | 24 (6.7) | 7 (5.7) | 17 (7.1) | 0.664 |
| Other | 5 (1.4) | 2 (1.6) | 3 (1.3) | 1.000 |
| Pre-existing comorbidities: | | | | |
| Arterial hypertension | 311 (86.4) | 106 (86.9) | 205 (86.1) | 1.000 |
| Diabetes mellitus | 43 (11.9) | 19 (15.6) | 24 (10.1) | 0.169 |
| Chronic obstructive pulmonary disease | 49 (13.6) | 19 (15.6) | 30 (12.6) | 0.516 |
| Coronary artery disease | 40 (11.1) | 11 (9.0) | 29 (12.2) | 0.479 |
| Obesity (BMI ≥30 kg/m$^2$) | 27 (7.5) | 10 (8.2) | 17 (7.1) | 0.833 |
| CMV IgG positivity | 312 (86.7) | 109 (89.3) | 203 (85.3) | 0.328 |
| EBV IgG positivity | 312 (86.7) | 107 (87.7) | 205 (86.1) | 0.745 |
| HSV IgG positivity | 286 (79.4) | 96 (78.7) | 190 (79.8) | 0.785 |
| VZV IgG positivity | 348 (96.7) | 118 (96.7) | 230 (96.6) | 1.000 |
| HBV viremia | 6 (1.7) | 1 (0.8) | 5 (2.1) | 0.668 |
| HCV viremia | 4 (1.1) | 1 (0.8) | 3 (1.3) | 1.000 |
| Previous kidney transplantation | 86 (23.9) | 33 (27.0) | 53 (22.3) | 0.361 |
| Last PRA (%) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.510 |
| N° Baseline DSA | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.440 |
| Baseline DSA | 23 (6.4) | 10 (8.2) | 13 (5.5) | 0.364 |
| HLA mismatch | 4 (3–5) | 4 (3–5) | 4 (3–5) | 0.345 |
| Length of hospitalisation | 13 (10–21) | 15 (10–20) | 13 (10–21) | 0.950 |
| ICU admission | 79 (21.9) | 26 (21.3) | 53 (22.3) | 0.893 |
| ICU stay (days) | 1 (1–2) | 1 (1–4) | 1 (1–1) | 0.080 |
| Induction immunosuppression: | | | | |
| Anti-IL2R antibodies | 179 (49.7) | 56 (45.9) | 123 (51.7) | 0.318 |
| rATG | 204 (56.7) | 75 (61.5) | 129 (54.2) | 0.217 |
| Methylprednisolone | 360 (100) | 122 (100) | 238 (100) | 1.000 |
| Anti-CD20 antibodies | 24 (6.3) | 7 (7.4) | 15 (6.3) | 0.824 |
| Anti-C5 antibodies | 34 (9.4) | 7 (5.7) | 27 (11.3) | 0.090 |
| Plasmapheresis | 37 (10.3) | 15 (12.3) | 22 (9.2) | 0.365 |
| Polyclonal human immunoglobulins | 31 (8.6) | 13 (10.7) | 18 (7.6) | 0.327 |

| | | | | |
|---|---|---|---|---|
| Maintenance immunosuppression: | | | | |
| Tacrolimus | 357/357 (100) | 120/120 (100) | 237/237 (100) | 1.000 |
| MMF/MPA | 347/357 (97.2) | 116/120 (96.7) | 231/237 (97.5) | 0.738 |
| Prednisone | 349/357 (97.8) | 117/120 (97.5) | 232/237 (97.9) | 1.000 |
| Tacrolimus trough levels (ng/ml): | | | | |
| After 1 month | 9.1 (7.6–11.0) | 9.1 (7.6–10.9) | 9.1 (7.5–11.1) | 0.773 |
| After 3 months | 8.8 (7.2–10.2) | 9.1 (7.1–10.2) | 8.4 (7.2–10.2) | 0.586 |
| After 6 months | 8.5 (7.0–10.0) | 8.9 (7.3–10.1) | 8.4 (6.9–10.0) | 0.295 |
| After 9 months | 7.9 (6.7–9.2) | 7.7 (6.5–8.6) | 7.9 (6.7–9.4) | 0.372 |
| After 12 months | 7.9 (6.6–9.4) | 8.1 (6.8–9.6) | 7.7 (6.5–9.3) | 0.501 |
| Follow-up (months) | 28.1 (13.2–37.8) | 34.9 (27.6–41.5) | 22.4 (10.4–43.6) | <0.001 |

Abbreviations: BMI, body mass index; CMV, cytomegalovirus; DSA, donor-specific antibody; EBV, Epstein-Barr virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HLA, human leukocyte antigen; HSV, herpes simplex virus; IgG, immunoglobulin G; IL2R, interleukin-2 receptor; MMF/MPA, mycophenolate mofetil / mycophenolic acid; PRA, panel re-active antibody; rATG, rabbit anti-thymocyte globulin; VZV, varicella-zoster virus